Anthropic Enters Drug Discovery for Neglected Diseases

The AI company is launching its own preclinical research programs targeting diseases that traditional pharma won't touch, framing the work as both a mission play and a way to sharpen its science AI tools.

Anthropic is launching its own drug discovery programs focused on neglected diseases — conditions that traditional pharmaceutical and biotech firms have passed on as unprofitable — with work beginning at the preclinical stage [1].

The company says the initiative fits its nonprofit mission and will also give it firsthand experience to build better AI models and tools for the broader industry [1]. The announcement came during an event for Anthropic’s new science AI tool, Claude Science [1].

What Claude Science can already do

The launch event included early demonstrations of AI-assisted research. A researcher at the University of California, San Francisco used Claude Science to detect a viral contamination in minutes — a problem his team had failed to catch for an entire year, according to Anthropic [1]. The company also says Claude analyzed 100 rare genetic diseases in under an hour and identified 32 candidates for computational screening [1].

How much time AI could actually cut from drug development

Novartis chief executive Vas Narasimhan, who spoke at the event, said getting a finished drug candidate from development to regulatory approval currently takes about twelve years [1]. He broke that delay into three buckets: information latency, operational latency, and biological latency [1].

New AI tools could significantly reduce the first two categories, which together account for roughly 40 percent of total development time, potentially bringing timelines down to seven or eight years [1]. Biological latency — the time required for animal testing, cell models, and human clinical trials — is unlikely to shrink much [1].

Narasimhan also sees a path to doubling drug success rates from 8 to 16 percent through better safety predictions and optimized molecular properties, though he noted the effect of improved patient selection remains unclear [1]. The hardest problem, he said, is still determining whether a drug target is biologically the right one for a given disease [1].

To put the stakes in context: the major pharmaceutical companies collectively spend $150 to $200 billion a year on research and development and have produced only 800 to 1,000 drugs over 120 years, according to Narasimhan [1]. Even modest efficiency gains, scaled across that base, could open up previously unreachable drug targets, he said [1].

A crowded field with cautious observers

Anthropic is not alone in pushing AI into drug development. DeepMind chief executive Demis Hassabis co-founded Isomorphic Labs with Alphabet to apply AI directly to drug discovery, and DeepMind’s protein-structure prediction tool AlphaFold remains one of the most prominent examples of AI in biology [1]. AlphaFold co-developer John Jumper recently left for Anthropic [1].

On the clinical side, Google DeepMind introduced an AI Co-Clinician in 2026 built around what it calls triadic care, where AI agents support patients throughout treatment while the physician retains clinical authority [1]. OpenAI launched ChatGPT Health in early 2026, a dedicated section within ChatGPT that lets users connect medical records, Apple Health data, and wellness apps [1].

Independent researchers urge caution, particularly when AI is applied in clinical settings for diagnoses, treatment plans, and direct patient care. Catherine Pope of the University of Oxford described results so far as “a piece removed from the messy, complex, human world of everyday healthcare” [1].


Sources

  1. The Decoder — Anthropic launches its own drug discovery programs to tackle diseases Big Pharma considers unprofitable

This article was drafted with AI from the cited sources and checked against them before publication. Spot an error? Let us know.

The AI company unveiled a scientific workbench for researchers and said it will pursue drug discovery for neglected diseases — a rare move for a frontier model maker.

Anthropic announced Claude Science, a new AI workbench for scientists, and said it plans to develop its own drugs, making it one of the first major frontier AI companies to pursue drug development directly [1].

The dual announcement came at an event called “The Briefing: AI for Science” earlier this week [1]. Claude Science is designed to pull fragmented tools and datasets into a single environment and generate figures and visuals for researchers [1]. Anthropic framed the launch around what it describes as AI’s potential to “dramatically accelerate the pace of scientific discovery and the development of healthcare interventions,” and pointed to an existing list of biotech and pharma customers already using Claude [1].

Going Beyond Software

The more unusual move is Anthropic’s stated intent to discover drugs itself. Eric Kauderer-Abrams, the company’s head of life sciences, said Anthropic will focus on treatments for “neglected” diseases [1]. The company did not respond to The Verge’s requests for additional detail — including which diseases it plans to target first, and whether it would partner with other organizations for lab work, animal testing, clinical trials, or manufacturing [1].

That puts Anthropic in the position of selling software to drugmakers who could also become its competitors [1]. It joins a field that already includes AI-first drug companies such as Insilico and Isomorphic Labs — a spinout from Google DeepMind — as well as biotech startups and large pharmaceutical companies building or acquiring AI tools [1]. OpenAI, Amazon, and Google also have their own life sciences tools and platforms [1].

To support the effort, Anthropic has been hiring biologists and building its own wet labs over the past year, and had several open life sciences roles at the time of publication [1]. Namshik Han, a professor at the University of Cambridge and co-founder of AI biotech startup CardiaTec, told The Verge that Anthropic has been “actively recruiting” in the area and that he believes the company has hired candidates away from Big Pharma and prestigious academic institutions [1].

What AI Can — and Cannot — Do in Drug Discovery

Experts who spoke with The Verge were measured about what AI can realistically deliver. Han said AI is applied at “every single stage of drug discovery,” from finding new compounds to supporting clinical trials and manufacturing [1]. Matthew Todd, a professor of drug discovery at University College London, called “AI drug discovery” a “catchall phrase” given how broadly the technology is used across the field [1].

AI can already help generate candidate molecules and speed up early research, Han said, for example by suggesting compounds that could interact with cell receptors already known to be involved in a particular disease [1]. Todd said it is useful for “road testing” new drug ideas [1]. Given Anthropic’s work on frontier models, the company would presumably use generative AI to search across large chemical and biological datasets and help researchers surface connections that would otherwise be slow to find [1].

But the path from AI-generated candidate to approved medicine remains long. Todd said the field is “a long way off” from an AI-designed drug receiving regulatory approval for human use, and stressed that the discovery process would not run autonomously — human input and supervision would be required throughout [1]. Both Todd and Han flagged a shortage of publicly available, high-quality experimental data on how chemicals behave in the body as a potential bottleneck, even in well-studied areas of biology [1].

Frank von Delft, a professor of structural chemical biology at the University of Oxford and head of protein crystallography at the Oxford Centre for Medicines Discovery, said AI models “haven’t yet come close to making experiments unnecessary” [1]. Drug candidates still need real-world testing for efficacy, toxicity, and practical properties such as safe preparation, storage, and delivery — work that requires skilled staff, significant funding, and time [1]. If Anthropic wants to develop a drug, von Delft said, it is “going to have to spend a lot on experiments” [1].

No AI-designed drug has yet completed clinical trials and received approval from the U.S. Food and Drug Administration (FDA) to reach market, though some AI-developed candidates have entered trials [1]. Todd noted there is “always a big lag time” with medicine testing, adding: “It takes time to show experimentally that something’s safe” [1]. Any payoff from Anthropic’s drug development effort is likely at least a decade away, given typical clinical trial timelines [1].


Sources

  1. The Verge — Anthropic wants to develop its own drugs

This article was drafted with AI from the cited sources and checked against them before publication. Spot an error? Let us know.

Anthropic unveiled Claude Science at an event for pharma and biotech leaders, positioning it as an autonomous research tool analogous to Claude Code for software engineering.

Anthropic has announced Claude Science, a new product designed to support scientific research, the company revealed at an event attended by pharmaceutical executives, biotech founders, and researchers. [1]

The product is modeled on Claude Code, Anthropic’s software-engineering tool, and is built to autonomously carry out meaningful work from concise, high-level instructions. [1] It includes tools specifically aimed at computational biology and drug development. [1]

Anthropic said it will also deploy Claude Science in its own internal research into drugs for rare and neglected diseases, signaling that the company intends to use the product beyond commercial licensing. [1]

The launch comes as the broader AI-for-drug-discovery space is attracting significant attention. On average, developing a new drug takes more than ten years and costs billions of dollars, and a growing number of startups are betting that machine-learning models can shorten that timeline by predicting how potential drug compounds might behave in the body and eliminating dead-end candidates before lab work begins. [1]

Separately, the United States lifted export restrictions on Anthropic’s Mythos and Fable models, with Anthropic saying it would begin restoring access on July 1, 2026, following lengthy talks with the company. [1] The controls had originally been imposed over security concerns, and reports indicate the crackdown had already created openings for Chinese AI rivals in affected markets. [1]


Sources

  1. MIT Technology Review — The Download: Anthropic launches Claude Science, and California’s carbon manure math

This article was drafted with AI from the cited sources and checked against them before publication. Spot an error? Let us know.